53590-65-1

Usage

Uses

Used in Pharmaceutical Industry:
7-Chloro-1h-indole-2-carbaldehyde is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
7-Chloro-1h-indole-2-carbaldehyde is used as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its reactivity and potential to form effective compounds for agricultural use.
Used in Research and Development:
7-Chloro-1h-indole-2-carbaldehyde is utilized as a versatile building block in the creation of complex organic molecules for research purposes, particularly in the fields of organic chemistry and medicinal chemistry, to explore new chemical entities and their potential applications.
Used in Drug Discovery:
7-Chloro-1h-indole-2-carbaldehyde is employed as a starting material in drug discovery processes, leveraging its indole core structure to develop novel compounds with potential therapeutic effects and pharmacological properties.

InChI:InChI=1/C9H6ClNO/c10-8-3-1-2-6-4-7(5-12)11-9(6)8/h1-5,11H

Upstream product

• 896137-69-2 7-chloro-1-(phenylsulfonyl)-1H-indole 
• 53924-05-3 7-chloro-1H-indole 

Relevant academic research and scientific papers

COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF

The present invention relates to novel Collagen 1 translation inhibitors, composition and methods of preparation thereof, and uses thereof for treating Fibrosis including lung, liver, kidney, cardiac and dermal fibrosis, IPF, wound healing, scarring and Gingival fibromatosis, Systemic Sclerosis, and alcoholic and non-alcoholic steatohepatitis (NASH).

IMIDAZO-PYRIDINE COMPOUNDS AS PAD INHIBITORS

Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosis, cutaneous lupus erythematosis, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis. The process of preparation of the compounds of Formula (I), (II), and (III), their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof, along with a pharmaceutical composition comprising a compound of Formula (I), Formula (II), Formula (III), or a pharmaceutically acceptable salt thereof have also been described.